Pharma BD Deal Intelligence
Catalent's $1 billion cash buy of Bettera's gummy and lozenge manufacturing looked like consumer-health expansion, but it soured: a non-cash goodwill impairment of more than $200 million hit Consumer Health in FY2023, and Catalent itself was later absorbed by Novo Holdings.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →The gummy supplement category continues its meteoric rise, with retail sales growing more than 30% annually since 2018 and reaching $5 billion in 2021. Drivers…
Catalent, Inc. has completed its $1 billion acquisition of Bettera Holdings, LLC, expanding its consumer health offerings into gummy, soft chew, and lozenge…
Form 8-K exhibit: completion of Novo Holdings acquisition of Catalent, Dec 18, 2024, $63.50/share, ~$16.5B enterprise value; Novo Nordisk concurrently acquired…
Source summaries from our enrichment pipeline; follow links for originals.
All 16 sources with sentiment breakdown →
Catalent agreed to acquire Bettera Holdings, a Plano, TX-based manufacturer of gummy, soft chew, and lozenge consumer health products, for $1B. The acquisition expanded Catalent's consumer health and nutraceuticals manufacturing platform. Post-close arc (added 2026-06-07): the deal underperformed against its original accretion thesis — in FY2023 Catalent recorded a non-cash goodwill impairment of more than $200M in its Consumer Health business tied primarily to the Bettera acquisition (part of a broader ~$700M / $689M Q1 FY2024 impairment). Catalent itself was subsequently acquired by Novo Holdings (completed Dec 18, 2024; $63.50/share; ~$16.5B enterprise value), with Bettera/Consumer Health passing into Novo Holdings ownership rather than being separately divested.
170M US cases/yr · $55.0B US dietary supplement retail sales 2021 (USD MM, NBJ Nutrition Business Journal) · 5000 US gummy-format dietary supplement sales 2021 (USD MM)
This deal is platform/CDMO in nature rather than indication-specific. The end-market is the global consumer health, dietary supplement and over-the-counter (OTC) nutraceutical category, with gummy and softgel dose forms being the fastest-growing segments. The US dietary supplement market reached approximately $55 billion in 2021 retail sales, with gummies — historically a children's vitamin niche — emerging as the dominant growth driver across multivitamins, melatonin, CBD, omega-3, biotin, ashwagandha, prenatal and immune-support categories. US gummy supplement sales grew from approximately $1.5 billion in 2018 to over $5 billion in 2021 at a 30%+ CAGR, materially outpacing tablet and capsule formats. Adult-targeted gummies drove most of the incremental growth, capturing 75-80% of category sales by 2021. The contract development and manufacturing organization (CDMO) opportunity for nutraceutical gummies grew commensurately as branded nutrition companies (Nature's Way, Olly, Vitafusion, MaryRuth's, Nature Made), retailer private labels (Costco Kirkland, Walmart Spring Valley, CVS, Walgreens) and DTC brands outsourced manufacturing capacity. Bettera Holdings was the third-largest US contract manufacturer of gummy/softgel/lozenge nutraceutical dose forms at deal date, with five FDA-registered facilities and ~$300M+ revenue capacity.
The nutraceutical CDMO landscape is highly fragmented. Catalent's primary competitors in contract gummy/softgel manufacturing include Procaps Group (Softigel division, public via SPAC late 2021, ~$420M revenue, dominant softgel CDMO in Latin America), Captek Softgel International (acquired by Catalent earlier as Catalent Softgel), Soft Gel Technologies, Alkemy Innovation, Vitaquest International, Stratum Nutrition, Best Formulations and Nutrasource. In gummies specifically, Bettera competed with Confab Confections, Tishcon, Bayer Consumer Health (One A Day own-manufacturing), Church & Dwight, Pharmavite/Otsuka (Nature Made own-mfg), and Twinlab. The broader pharma/biopharma CDMO competitive set — relevant because Catalent leverages cross-sell — includes Lonza Group, Thermo Fisher Patheon, Samsung Biologics, WuXi Biologics, WuXi STA, Recipharm, Siegfried, Cambrex, Piramal Pharma Solutions and Aenova. Strategic rationale: Catalent paid $1.0 billion cash to acquire scale leadership in gummy/softgel/lozenge consumer health dose forms, capitalizing on the gummy supplement CAGR and broadening Catalent's small-molecule/oral-dose-form portfolio beyond pharma into higher-growth consumer health adjacencies. Deal expected to be accretive to FY2022 EPS.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Catalent, Inc. / Bettera Holdings, LLC (this deal) | 2021 | $1.0B | — |
| Catalent, Inc. / Paragon Bioservices, Inc. | 2019 | $1.2B | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
← Browse all deals · How we score deals
More: 2021 deals · Other deals